Abstract
Patent and regulatory hurdles combined with low returns on investment are stifling antibiotic R&D in the pharmaceutical industry.
MeSH terms
-
Anti-Bacterial Agents*
-
Drug Approval / economics*
-
Drug Approval / legislation & jurisprudence
-
Drug Design*
-
Humans
-
Patents as Topic / legislation & jurisprudence*
-
Research / economics*
-
Research / trends